참고문헌
- Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-99. https://doi.org/10.1016/S0140-6736(17)30933-9
- Brown M, O'Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310-21.
- Su M, Tian F, Ouyang B, Wu X, Guo F, Chen H, et al. Bufei Qingyu Granules Inhibit the Development of Systemic Sclerosis via Notch-1/Jagged-2 Signaling Pathway. Evid Based Complement Alternat Med. 2019;2019:6709278.
- Bian H, Fan YS, Lou LH, Mao BY, Shi JY. [Effect of Wenyang Huazhuo Tongluo recipe contained serum on proliferation and cell cycle of systemic sclerosis skin fibroblasts]. Zhong Yao Cai. 2009;32(6):936-9.
- Bian H, Lv Q, Huang XZ, Hu JL, Yang L, Mao BY. [Effects of Wenyang Huazhuo Tongluo Recipe Containing Serum on Transforming Growth Factor beta1/ Smad Signaling Pathway of Skin Fibroblasts in Systemic Sclerosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(9): 1054-9.
- Han L, Bian H, Ouyang J, Bi Y, Yang L, Ye S. Wenyang Huazhuo Tongluo formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis. BMC Complement Altern Med. 2016;16:69. https://doi.org/10.1186/s12906-016-1056-6
- Wang Q, Zang W, Han L, Yang L, Ye S, Ouyang J, et al. Wenyang Huazhuo Tongluo formula inhibits fibrosis via suppressing Wnt/beta-catenin signaling pathway in a Bleomycin-induced systemic sclerosis mouse model. Chin Med. 2018;13:17. https://doi.org/10.1186/s13020-018-0175-z
- Wu T, Chu H, Tu W, Song M, Chen D, Yuan J, et al. Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis. BMC Complement Altern Med. 2014;14:224. https://doi.org/10.1186/1472-6882-14-224
- Wang Q, Shi G, Zhang Y, Lu F, Xie D, Wen C, et al. Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. Sci Rep. 2019;9(1):355. https://doi.org/10.1038/s41598-018-36314-2
- Qi Q, Mao Y, Yi J, Li D, Zhu K, Cha X. Anti-fibrotic effects of Astragaloside IV in systemic sclerosis. Cell Physiol Biochem. 2014;34(6):2105-16. https://doi.org/10.1159/000366405
- Qi Q, Mao Y, Tian Y, Zhu K, Cha X, Wu M, et al. Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model. Am J Transl Res. 2017;9(3):1025-36.
- Liu Q, Lu J, Lin J, Tang Y, Pu W, Shi X, et al. Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis. Biomed Pharmacother. 2019;110:546-53. https://doi.org/10.1016/j.biopha.2018.12.016
- Jiang Y, Hu F, Li Q, Shen C, Yang J, Li M. Tanshinone IIA ameliorates the bleomycin-induced endothelial-to- mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis. Int Immunopharmacol. 2019;77:105968. https://doi.org/10.1016/j.intimp.2019.105968
- Bian H, Yuan M, Gao Z-m, Bi XD, Han L, Hu JL, et al. [Effect of Wenyang Huazhuo Tongluo Recipe on Peripheral Blood Thl7/Treg Cell Balance in Systemic Sclerosis Patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(8):975-80.
- Zhou J, Yang D, Zhou SH, Wang JP, Liu YS, Wang SL. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial. Chin J Integr Med. 2018;24(3):185-92. https://doi.org/10.1007/s11655-017-2954-2
- Jang S, Yoon S, Ryu J, Lim J, Han S, Kim H, et al. A Case Report of Korean Traditional Medical Therapy on Gastric Dysmotility Involved in Patient with Systemic Sclerosis Sine Scleroderma. Korean J Orient Int Med. 2004;25(2):344-51.
- Liu XS, Gao Y, Zheng LW, Hua H. New alternative therapy for orofacial localized scleroderma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(3):e15-9.
- Kim MK, Jeong JG, Kim KM, Kim HJ, Kim JH, Kim YI, et al. The Effect of Korean Medical Treatment on Systemic Sclerosis : A Case Report. The Acupuncture. 2016;33(3):207-18. https://doi.org/10.13045/acupunct.2016048
- Jang Y, Kim J, Kim H, Lee G, Lim S. A Case of Raynaud's Syndrome Modified by Secondary Systemic Sclerosis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31(4): 108-16. https://doi.org/10.6114/JKOOD.2018.31.4.108
- Park SH, Do TY, Lee SH, Lee JY. A Case Report of Clinical Effects of Complex Korean Medicine Treatment in Patients with Scleroderma Caused by Juvenile Idiopathic Arthritis. J Pediatr Korean Med. 2019;33(4):26-36.
- Kim H. Updated Classification Criteria for Systemic Sclerosis: the Concept of Early Diagnosis. The Korean Journal of Medicine. 2014;87(4):395-400. https://doi.org/10.3904/kjm.2014.87.4.395
- Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castaneda AR, et al. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. Biomed Res Int. 2019;2019:4569826. https://doi.org/10.1155/2019/4569826
- Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088-93. https://doi.org/10.1136/ard.62.11.1088
- Asano Y. Systemic sclerosis. J Dermatol. 2018;45(2):128-38. https://doi.org/10.1111/1346-8138.14153
- Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-39. https://doi.org/10.1136/annrheumdis-2016-209909
- Oliver GF, Winkelmann RK. The current treatment of scleroderma. Drugs. 1989;37(1):87-96. https://doi.org/10.2165/00003495-198937010-00006
- Barsotti S, Orlandi M, Codullo V, Di Battista M, Lepri G, Della Rossa A, et al. One year in review 2019: systemic sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 119(4):3-14.
- Heo J. DongEuiBoGam. 1st ed. Seoul: Publisher DongEuiBoGam. 2006:1023.
- Editorial board of Traditional Korean Dermatology&Surgery. Text of Traditional Korean Dermatology & Surgery. 1st ed. Seoul: Seon Woo. 2007:484.
- Yang Y, Yang S, Chen M, Zhang X, Zou Y, Zhang X. Compound Astragalus and Salvia miltiorrhiza Extract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts. J Ethnopharmacol. 2008;118(2):264-70. https://doi.org/10.1016/j.jep.2008.04.012
- Kim DH, Jung YS, Yoon M, Yoon Y, Shin SS. Analysis for Compatibility of Gyejibongnyeong-hwan and Its Biological Activities. Herbal Formula Science. 2016;24(4):353-65. https://doi.org/10.14374/HFS.2016.24.4.353
- Editorial board of Herbal Formula Science in Korean Medicine. Herbal Formula Science in Korean Medicine. 1st ed. Seoul: Koonja. 2020:998.
- Editorial board of Herbalogy. Herbalogy. 1st ed. Seoul: Younglimsa. 2004:210, 461, 580.
- Liu H, Wei W, Sun WY, Li X. Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells. J Ethnopharmacol. 2009;122(3):502-8. https://doi.org/10.1016/j.jep.2009.01.035
- Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int. 2007;51(6-7):361-9. https://doi.org/10.1016/j.neuint.2007.04.021
- Peng CH, Huang CN, Hsu SP, Wang CJ. Penta-acetyl geniposide-induced apoptosis involving transcription of NGF/p75 via MAPK-mediated AP-1 activation in C6 glioma cells. Toxicology. 2007;238(2-3):130-9. https://doi.org/10.1016/j.tox.2007.05.029
- Park JH, Yoon J, Lee KY, Park B. Effects of geniposide on hepatocytes undergoing epithelial-mesenchymal transition in hepatic fibrosis by targeting TGFbeta/Smad and ERK-MAPK signaling pathways. Biochimie. 2015;113:26-34. https://doi.org/10.1016/j.biochi.2015.03.015
- Yang K, Luo Y, Lu S, Hu R, Du Y, Liao P, et al. Salvianolic Acid B and Ginsenoside Re Synergistically Protect Against Ox-LDL-Induced Endothelial Apoptosis Through the Antioxidative and Antiinflammatory Mechanisms. Front Pharmacol. 2018;9:662. https://doi.org/10.3389/fphar.2018.00662
- Yu F, Lu Z, Chen B, Wu X, Dong P, Zheng J. Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT1-mediated Patched1 methylation. J Cell Mol Med. 2015;19(11):2617-32. https://doi.org/10.1111/jcmm.12655
- Liu M, Xu H, Zhang L, Zhang C, Yang L, Ma E, et al. Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2. Biochem Biophys Res Commun. 2018;495(1):325-31. https://doi.org/10.1016/j.bbrc.2017.11.014
- Luan L, Liang Z. Tanshinone IIA protects murine chondrogenic ATDC5 cells from lipopolysaccharide-induced inflammatory injury by down-regulating microRNA-203a. Biomed Pharmacother. 2018;103:628-36. https://doi.org/10.1016/j.biopha.2018.04.051
- Cao L, Huang B, Fu X, Yang J, Lin Y, Lin F. Effects of tanshinone IIA on the regulation of renal proximal tubular fibrosis. Mol Med Rep. 2017;15(6):4247-52. https://doi.org/10.3892/mmr.2017.6498
- Balanescu P, Balanescu E, Balanescu A. IL-17 and Th17 cells in systemic sclerosis: a comprehensive review. Rom J Intern Med. 2017;55(4):198-204. https://doi.org/10.1515/rjim-2017-0027
- Lee BW, Kim SC, Byun SH, Kim HK, Jee SY. Study on Duties and Abilities of a Human's Mentality[five kinds of mental activities]-Oriental Medicine's Outlook on Mentality-. J Korean Med Classics. 2004;17(1): 198-217.